efzofitimod 450 mg + efzofitimod 270 mg + Placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Lung Disease
Conditions
Interstitial Lung Disease
Trial Timeline
Oct 26, 2023 → Apr 1, 2026
NCT ID
NCT05892614About efzofitimod 450 mg + efzofitimod 270 mg + Placebo
efzofitimod 450 mg + efzofitimod 270 mg + Placebo is a phase 2 stage product being developed by aTyr Pharma for Interstitial Lung Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05892614. Target conditions include Interstitial Lung Disease.
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Lung Disease were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05892614 | Phase 2 | Recruiting |
Competing Products
20 competing products in Interstitial Lung Disease